Luxturna Secures English Reimbursement In Record Time
Executive Summary
Novartis/Spark’s Luxturna has been authorized by NICE for use in England after the company agreed a discount on the list price that made the gene therapy cost effective for the national health service. The recommendation was made in record time thanks to good collaboration between the two parties.
You may also be interested in...
Novartis’s Early HTA Engagement Pays Off With Luxturna
NICE’s rapid decision to recommend funding in England and Wales for Novartis’s gene therapy Luxturna is a result of what the company calls its "collaborative and transparent" approach to negotiations over the health technology assessment of innovative new therapies. Novartis explains why this appraisal process was completed so quickly.
AI Focus At NHSX Lets Clinicians 'Function At The Top Of Their License'
Less than 2% of NHS England’s budget is spent on digital technology, compared with 4-5% in other industries, NHS chief information officer Dr. Simon Eccles told delegates at the NHS Health and Care Innovation Expo 2019 this week. But the new NHS AI Lab is seen as a big step in the right direction.
Luxturna's EU Approval Highlights Gene Therapy Pricing Challenges
Novartis/Spark Therapeutics’ transformative gene therapy Luxturna has just been approved in the EU. Like other gene therapies, it comes with a heavy price tag. So how will Novartis convince payers to pay, and how will payers cope with expensive, game changing therapies in the future?